Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desflurane
Drug ID BADD_D00611
Description Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Indications and Usage Desflurane is indicated for the induction and maintenance of anesthesia in adults, as well as the maintenance of anesthesia in pediatric patients.[L30285]
Marketing Status approved
ATC Code N01AB07
DrugBank ID DB01189
KEGG ID D00546
MeSH ID D000077335
PubChem ID 42113
TTD Drug ID D0H4GN
NDC Product Code 0404-9961; 52584-641; 66794-021; 0781-6172; 10019-641; 57884-0028; 10019-644; 10019-646
UNII CRS35BZ94Q
Synonyms Desflurane | 1,2,2,2-Tetrafluoroethyl difluoromethyl ether | I 653 | I-653 | I653 | Suprane
Chemical Information
Molecular Formula C3H2F6O
CAS Registry Number 57041-67-5
SMILES C(C(F)(F)F)(OC(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory depression17.02.05.047; 22.02.01.010---
Respiratory distress22.02.01.012---
Respiratory failure14.01.04.003; 22.02.06.0020.000179%
Rhabdomyolysis15.05.05.002--
Salivary hypersecretion07.06.01.009---
Seizure17.12.03.001--
Shock24.06.02.002---
Tachycardia02.03.02.0070.000179%-
Tachypnoea22.02.01.014---
Torsade de pointes02.03.04.005---
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.007---
Ventricular tachycardia02.03.04.0100.000179%
Visual acuity reduced06.02.10.012; 17.17.01.011--
Vomiting07.01.07.003--
White blood cell count increased13.01.06.013---
Tachyarrhythmia02.03.02.008---
Ventricular hypokinesia02.04.02.013---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Conjunctival hyperaemia06.04.01.004---
Lymphatic disorder01.09.01.003---
Foetor hepaticus07.01.06.026; 09.01.05.006---
Musculoskeletal discomfort15.03.04.001---
Skin burning sensation17.02.06.009; 23.03.03.021---
Transaminases increased13.03.04.036---
Haemorrhage24.07.01.002---
Ocular icterus01.06.04.007; 06.08.03.009; 09.01.01.007---
Vasodilation procedure25.03.01.001---
Angiopathy24.03.02.007---
Ventricular failure02.05.01.007---
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene